ClinicalTrials.govpublic full text
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
psoriasis, skin diseases, skin diseases, papulosquamous, ustekinumab, dermatologic agents, abbv-066, bi 655066, risankizumab, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 904822
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.